Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4585 Short-term observation of liver transplantation combined with multidisciplinary integrated treatment of liver metastases from neuroendocrine tumours beyond the Milan criteria

Introduction: The continuous progress of comprehensive treatment enables neuroendocrine tumour liver metastasis (NENLM) that meets Milan criteria to achieve longer survival without liver transplantation (LT). LT often faces high tumour burden, while comprehensive treatment also brings new opportunities for recurrence.

Conference:

Presenting Author: Chen C

Authors: Chen C, Jiang W, Chen J, Liang Y, Xie Y,

Keywords: liver transplantation, neuroendocrine tumour liver metastasis, Milan Criteria, comprehensive treatment,

#4490 Parietal cell-selective Slc26a9 deletion in mice causes gasdermin D mediates mitochondrial damage and pyroptosis, which is the key event to induce autoimmune gastritis

Introduction: Autoimmune gastritis (AIG) is the basis of gastric malignancy, including neuroendocrine tumour (NET) and gastric cancer (GC). We reported that Slc26a9 is highly expressed in parietal cells (PCs), and its deficiency caused GC.

Conference:

Presenting Author: Liu X

Authors: Ji B, Deng Z, Ma Z, Li T, Tuo B,

Keywords: Slc26a9, autoimmune gastritis, Pyroptosis, gastric mucosal immunity remodelling,

#4399 Updated data from a single-arm, open-label, multicentre clinical study on the efficacy and safety of surufatinib combined with EP regimen and serplulimab in first-line treatment of NEC

Introduction: NEC is an aggressive neuroendocrine neoplasm with limited treatment options. Surufatinib (SUR), a kinase inhibitor targeting VEGFRs, FGFR-1, and CSF-1R, improves vascular normalisation and tumour microenvironment, synergising with chemo- and immunotherapy.

Conference:

Presenting Author: Lin Z

Authors: Zhang T, Lin Z, Zhao L, Ma H, Zhang D,

Keywords: NEC, surufatinib, EP, first-line,

#4368 Surgical and multidisciplinary management of pancreatic neuroendocrine tumours with liver metastases: Insights from a high-volume centre

Introduction: Pancreatic neuroendocrine tumours (pNETs) are rare, with liver metastases posing significant prognostic challenges. MEN1-associated pNETs often present with multifocal and complex disease, requiring a tailored, multidisciplinary approach.

Conference:

Presenting Author: Yuntao B

Authors: Yuntao B, Chunhui Y, Lei L,

Keywords: Pancreatic Neuroendocrine Tumour, Liver Metastasis, MEN1, Multidisciplinary Team, Surgical Resection, Ki-67 Index, SSA, PRRT,

#4205 Precision medicine in advanced NENs: Molecular profiling and target actionability real world data

Introduction: Molecular profiling (MP) of NENs is not performed on routine basis and its potential clinical use is a matter of debate.

Conference:

Presenting Author: Farinea G

Authors: Farinea G, Anton-Pascual B, Catoya J, Modrego A, La Salvia A,

Keywords: Genomic Profiling, ESCAT, NEN, Precision Medicine,